Last reviewed · How we verify
NCT02829827
A Phase 2 Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)
Phase 2 trial testing Radiprodil in Infantile Spasms (IS) in 3 participants. Terminated before completion.
2 October 2018
Quick facts
| Lead sponsor | UCB Biopharma S.P.R.L. |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 3 |
| Start date | 4 December 2017 |
| Primary completion | 2 October 2018 |
| Estimated completion | 2 October 2018 |
| Sites | 1 location across France |
Drugs / interventions tested
- Radiprodil — full drug profile →
Conditions studied
- Infantile Spasms (IS) — all drugs for Infantile Spasms (IS) →
Sponsor
UCB Biopharma S.P.R.L. — full company profile →
Who can join
Adults 2 Months to 14 Months, any sex, with Infantile Spasms (IS). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to evaluate the safety and tolerability, the pharmacokinetics and the efficacy of radiprodil in abolishing clinical spasms in subjects with drug-resistant infantile spasms
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Allosteric Modulation of Ionotropic Glutamate Receptors: An Outlook on New Therapeutic Approaches To Treat Central Nervous System Disorders.
Brogi S, Campiani G, Brindisi M, Butini S. · · 2019 · cited 31× · PMID 30891118 · DOI 10.1021/acsmedchemlett.8b00450 -
Radiprodil, a NR2B negative allosteric modulator, from bench to bedside in infantile spasm syndrome.
Auvin S, Dozières-Puyravel B, Avbersek A, Sciberras D, et al · · 2020 · cited 26× · PMID 32106360 · DOI 10.1002/acn3.50998 -
A pharmacokinetic study of radiprodil oral suspension in healthy adults comparing conventional venous blood sampling with two microsampling techniques.
Sciberras D, Otoul C, Lurquin F, Smeraglia J, et al · · 2019 · cited 18× · PMID 30705758 · DOI 10.1002/prp2.459
Verify or expand the search:
- PubMed search for NCT02829827
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other UCB Biopharma S.P.R.L. trials
Trials by the same sponsor.
- NCT04136444 — A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function · Phase 1 · terminated
- NCT04126343 — A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants · Phase 1 · terminated
- NCT04075409 — A Study to Test the Safety, and Tolerability of Padsevonil in Healthy Male Japanese Study Participants · Phase 1 · completed
- NCT04039919 — A Study to Test the Pharmacodynamic, Pharmacokinetic, Safety, and Tolerability of Padsevonil in Healthy Study Participan · Phase 1 · terminated
- NCT04013191 — A Study to Test the Safety and Tolerability of Single and Multiple Doses of Padsevonil in Adult and Elderly Study Partic · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02829827 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by UCB Biopharma S.P.R.L.
- Last refreshed: 17 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02829827.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing